Teneligliptin


Generic Medicine Info
Indications and Dosage
Oral
Type 2 diabetes mellitus
Adult: As monotherapy or in combination with other hypoglycaemic agents: 20 mg once daily; may increase to 40 mg once daily if effect is inadequate.
Administration
tab: May be taken with or without food. Preferably taken before meals.
Contraindications
Severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infections, surgery, severe trauma.
Special Precautions
Patient with pituitary or adrenal insufficiency, poor nutritional state, starvation, irregular food intake, history of bowel obstruction or abdominal surgery, heart failure NYHA functional class III-IV, active or history of arrhythmia, bradycardia, low K levels, Torsades de pointes, QT prolongation. Intensive exercise or excessive alcohol intake. Debilitated patients. Severe hepatic impairment. Pregnancy and lactation.
Adverse Reactions
Significant: Hypoglycaemia, hepatic impairment (accompanied by increased AST/ALT), intestinal obstruction, bullous pemphigoid, interstitial pneumonia, prolonged QT interval. Rarely, acute pancreatitis.
Gastrointestinal disorders: Abdominal distension, discomfort or pain; constipation, flatulence, nausea, stomatitis, gastric or colonic polyps, duodenal ulcer, reflux oesophagitis, diarrhoea.
General disorders and administration site conditions: Malaise.
Investigations: Elevated amylase, lipase, γ-GTP, creatine phosphokinase, serum K and uric acid.
Metabolism and nutrition disorders: Decreased appetite.
Renal and urinary disorders: Proteinuria, presence of ketones in urine, haematuria.
Respiratory, thoracic and mediastinal disorders: Allergic rhinitis.
Skin and subcutaneous tissue disorders: Eczema, rash, itching, allergic dermatitis.
Patient Counseling Information
This drug may cause dizziness or weakness due to lowering of blood sugar, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor plasma glucose, HbA1c (at least twice yearly in patients who have stable glycaemic control and are meeting treatment goals; quarterly in patients not meeting treatment goals or with therapy change), liver function. Monitor for signs/symptoms of pancreatitis (e.g. severe abdominal pain, anorexia, nausea, vomiting).
Drug Interactions
Increased hypoglycaemic effects with other antidiabetics (e.g. sulfonylureas, insulins, biguanides), β-blockers, MAOIs, salicylic acid. Reduced hypoglycaemic effect with epinephrine, adrenocortical and thyroid hormones. Increased risk of QT prolongation with Class 1A (e.g. procainamide, quinidine) and Class III antiarrhythmics (e.g. amiodarone, sotalol).
Action
Description: Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4), an enzyme involved in the degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) leading to increased and prolonged active incretin levels. These incretin hormones enhance insulin release and inhibit glucagon secretion resulting in reduced blood glucose level.
Pharmacokinetics:
Absorption: Rapidly absorbed. Time to peak plasma concentration: 1-1.3 hours.
Distribution: Plasma protein binding: 77.6-82.2%.
Metabolism: Metabolised in the liver by CYP3A4 and flavin monooxygenases (FMO) 1 and 3 to several metabolites.
Excretion: Via urine (21-34%, as unchanged drug). Elimination half-life: 18.9-26.9 hours.
Chemical Structure

Chemical Structure Image
Teneligliptin

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 11949652, Teneligliptin. https://pubchem.ncbi.nlm.nih.gov/compound/Teneligliptin. Accessed Feb. 22, 2022.

Storage
Store below 30°C.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH08 - teneligliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
References
Anon. Teneligliptin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/01/2022.

Buckingham R (ed). Teneligliptin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/01/2022.

Glipten 20 mg Film-Coated Tablet (Ajanta Pharma Limited). MIMS Philippines. http://www.mims.com/philippines. Accessed 05/01/2022.

Tenelia 20 mg Tablets (Mitsubishi Tanabe Pharma Factory Ltd). MIMS Thailand. http://www.mims.com/thailand. Accessed 05/01/2022.

Disclaimer: This information is independently developed by MIMS based on Teneligliptin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in